Pages Menu
TwitterFacebook
Categories Menu

Posted by on Dec 3, 2020 in Uncategorized | 0 comments

Astrazeneca Oxford Vaccine Agreement

AstraZeneca recently partnered with the UK government to support the Oxford University vaccine and has made rapid progress in its efforts to expand access worldwide. The company will supply the UK from September and is grateful for the government`s commitment and for all the work on vaccines. AstraZeneca will initially pay Oxford Biomedica $20 million to reserve 1,000 litres of production capacity for its COVID-19 BASED AZD1222 Adenovirus vaccine for at least 18 months, as the companies announced on Monday. AstraZeneca develops shooting with the University of Oxford. Oxford University announced last month the launch of a Phase II/III study conducted by the United Kingdom on AZD1222 on approximately 10,000 adult volunteers. Further trials at the end of the period will begin in a number of countries. AstraZeneca acknowledges that the vaccine may not work, but is committed to accelerating the clinical program and accelerating production. The news of the deal came when AstraZeneca announced monday night that it had begun late studies of the vaccine in the United States, where it plans to enroll 30,000 adults in a global product testing program on 50,000 people. AstraZeneca today received more than $1 billion in support from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine starting in the fall. The development program includes a Phase III clinical study involving 30,000 participants and a pediatric study. With today`s agreement, the IVA intends to accelerate the supply of vaccines and make available to other European countries wishing to participate in the initiative. The IVA is committed to ensuring equal access for all participating countries throughout Europe.

Oxford Biomedica followed in June with its VMIC agreement to accelerate production of AstraZeneca and other vector viral vaccines. Today`s announcement is not expected to have a significant impact on the company`s 2020 financial forecast; The cost of advancing the vaccine should be offset by government funding. Mene Pangalos, Executive Vice President, BioPharmaceuticals Research and Development, AstraZeneca, said: “The University of Oxford and AstraZeneca have a long-standing relationship to advance basic research and we are very pleased to work with them to develop a vaccine to prevent COVID-19 worldwide. We look forward to working with Oxford University and innovative companies like Vaccitech as part of our new partnership. The company has entered into the first agreements for at least 400 million doses and has guaranteed the total production capacity of one billion doses to date and will begin its first deliveries in September 2020. AstraZeneca is working to conclude other agreements, supported by several parallel supply chains, that will further strengthen capacity in the coming months to ensure the delivery of a globally accessible vaccine.